Therapeutic AIDS vaccines

Current Pharmaceutical Design

Volumn 12, Issue 16, 2006, Pages 2017-2030

  Bourinbaiar, A S ^a   Root Bernstein, R S ^b   Abulafia Lapid, R ^c   Rytik, P G ^d   Kanev, A N ^e   Jirathitikal, V ^a   Orlovsky, V G ^f  

^a Immunitor USA Inc   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d Research Institute for Epidemiology & Microbiology RIEM   (Belarus)

^e STATE RESEARCH CENTER OF VIROLOGY AND BIOTECHNOLOGY VECTOR   (Russian Federation)

^f Novosibirsk Regional Center for AIDS Prophylaxis and Prevention   (Russian Federation)

Author keywords

Alloimmunity; ARV; Autoimmunity; Autologous; HAART; Immunotherapy; Mucosa

Indexed keywords

ALPHA INTERFERON; ANTIGEN; ANTIIDIOTYPIC ANTIBODY; ANTIINFLAMMATORY AGENT; ANTIRETROVIRUS AGENT; DENDRITIC CELL VACCINE; DNA VACCINE; ERYTHROPOIETIN ANTIBODY; GLATIRAMER; HEAT SHOCK PROTEIN 60; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN; INSULIN; LIVE VACCINE; NAKED DNA; PEPTIDE VACCINE; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 2; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VIRUS VACCINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOIMMUNIZATION; ANEMIA; AUTOIMMUNE DISEASE; CELL CULTURE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DOSE REGIMEN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LEUKEMIA; LYMPHOCYTE TRANSFUSION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRION; VIRUS CARRIER; VIRUS PARTICLE;

AIDS VACCINES; CYTOKINES; DENDRITIC CELLS; HIV; HUMANS; IMMUNOTHERAPY, ACTIVE; LEUKOCYTES, MONONUCLEAR; VACCINES, DNA; VIRAL PROTEINS;

EID: 33744739178     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777442119     Document Type: Review

References (176)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Out-patient Study Investigators. N Engl J Med 1998; 338: 853-60.
2. Gilliam BL, Redfield RR. Therapeutic HIV vaccines. Curr Top Med Chem 2003; 3: 1536-53.
3. Robbins GK, Addo MM, Troung H, Rathod A, Habeeb K, Davis B, et al. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS 2003; 17: 1121-6.
4. Egan MA. Current prospects for the development of a therapeutic vaccine for the treatment of HIV type 1 infection. AIDS Res Hum Retrovir 2004; 20: 794-806.
5. Zagury D, Leonard R, Fouchard M, Reveil B, Bernard J, Ittele D, et al. Immunization against AIDS in humans. Nature 1987; 326: 249-250.
6. Picard O, Giral P, Defer MC, Fouchard M, Morel M, Meyohas MC, et al. AIDS vaccine therapy: phase I trial. Lancet 1990; 336: 179.
7. Redfield RR, Birx DL, Ketter N, Tramont E, Polonis V, Davis C, et al. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med 1991; 321: 1677-1684.
8. Birx DL, Loomis-Price LD, Aronson N, Brundage J, Davis C, Deyton L, et al. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators. J Infect Dis 2000; 181: 881-889.
9. Valentine FT, Kundu S, Haslett PA, Katzenstein D, Beckett L, Spino C, et al. A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). J Infect Dis 1996; 173: 1336-1346.
10. Sandstrom E, Wahren B. Therapeutic immunization with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet 1999; 353: 1735-1742.
11. Goebel FD, Mannhalter JW, Belshe RB, Eibl MM, Grob PJ, de Gruttola V, et al. Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group. AIDS 2000; 13: 1461-1468.
12. Pontesilli O, Guerra EC, Aminassari A, Tomino C, Carlesimo M, Antinori A, et al. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team. AIDS 1998; 12: 473-480.
13. Lambert JS, McNamara J, Katz SL, Fenton T, Kang M, VanCott TC, et al. Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG-218). J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 451-461.
14. Essajee SM, Yogev R, Pollack H, Greenhouse B, Krasinski K, Borkowsky W. Recombinant glycoprotein vaccines for human immunodeficiency virus-infected children and their effects on viral quasispecies. Clin Diagn Lab Immunol 2002; 9: 79-82.
15. Wright PF, Lambert JS, Gorse GJ, Hsieh RH, McElrath MJ, Weinhold K, et al. Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women. J Infect Dis 1999; 180: 1080-1088.
16. Tsoukas CM, Raboud J, Bernard NF, Montaner JS, Gill MJ, Rachlis A, et al. Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency. AIDS Res Hum Retrovir 1998; 14: 483-90.
17. Schwander S, Opravil M, Luthy R, Hanson DG, Schindler J, Dawson A, et al. Phase I/II vaccination study of recombinant peptide F46 corresponding to the HIV-1 transmembrane protein coupled with 2.4 dinitrophenyl (DNP) Ficoll. Infection 1994; 22: 86-91.
18. Bartlett JA, Wasserman SS, Hicks CB, Dodge RT, Weinhold KJ, Tacket CO, et al. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. AIDS 1998; 12: 1291-1300.
19. Sha BE, Onorato M, Bartlett JA, Bosch RJ, Aga E, Nokta M, et al. Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. AIDS 2004; 18: 1203-6.
20. Pinto LA, Berzofsky JA, Fowke KR, Little RF, Merced-Galindez F, Humphrey R, et al. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS 1999; 13: 2003-2012.
21. Seth A, Yasutomi Y, Jacoby H, Callery JC, Kaminsky SM, Koff WC, et al. Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals. AIDS Res Hum Retroviruses 2000; 16: 337-343.
22. Asjo B, Stavang H, Sorensen B, Baksaas I, Nyhus J, Langeland N. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy. AIDS Res Hum Retrovir 2002; 18: 1357-1365.
23. Gringeri A, Santagostino E, Muca-Perja M, Mannucci PM, Zagury JF, Bizzini B, et al. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J Hum Virol 1998; 1: 293-8.
24. Blazevic V, Ranki A, Krohn KJ. Helper and cytotoxic T cell responses of HIV type 1-infected individuals to synthetic peptides of HIV type 1 Rev. AIDS Res Hum Retrovir 1995; 11: 1335-42.
25. Naylor PH, Naylor CW, Badamchian M, Wada S, Goldstein AL, Wang SS, et al. Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30. Proc Natl Acad Sci USA 1987; 84: 2951-5.
26. Boucher CA, Krone WJ, Goudsmit J, Meloen RH, Naylor PH, Goldstein AL, et al. Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30. J Clin Lab Anal 1990; 4: 43-7.
27. Naylor PH, Sztein MB, Wada S, Maurer S, Holterman D, Kirkley JE, et al. Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine - HGP-30-KLH. Int J Immunopharmacol 1991; 13: 117-27.
28. Jiang JD, Chu FN, Naylor PH, Kirkley JE, Mandeli J, Wallace JI, et al. Specific antibody responses to synthetic peptides of HIV-1 p17 correlate with different stages of HIV-1 infection. J Acquir Immune Defic Syndr 1992; 5: 382-90.
29. Willer A, Achour A, Mbika JP, Laaroubi K, Lachgar A, Nihrane A, et al. Cell-mediated immunity against HGP-30, a group-specific peptide of HIV p17 in individuals infected with the AIDS virus. Biomed Pharmacother 1992; 46: 359-65.
30. Achour A, Picard O, Zagury D, Sarin PS, Gallo RC, Naylor PH, et al. HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals. Proc Natl Acad Sci USA 1990; 87: 7045-9.
31. Clerici M, Lucey Di, Zajac RA, Boswell RN, Gebel HM, Takahashi H, et al. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J Immunol 1991; 146: 2214-9.
32. Ahlers JD, Pendleton CD, Dunlop N, Minassian A, Nara PL, Berzofsky JA. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations. J Immunol 1993; 150: 5647-65.
33. Boyer JD, Chattergoon MA, Ugen KE, Shah A, Bennett M, Cohen A, et al. Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial. Clin Immunol 1999; 90: 100-107.
34. MacGregor RR, Boyer JD, Ciccarelli RB, Ginsberg RS, Weiner DB. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data. J Infect Dis 2000; 181: 406.
35. Lundholm P, Leandersson AC, Christensson B, Bratt G, Sandstrom E, Wahren B. DNA mucosal HIV vaccine in humans. Virus Res 2002; 82: 141-5.
36. Hejdeman B, Bostrom AC, Matsuda R, Calarota S, Lenkei R, Fredriksson EL, et al. DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy. AIDS Res Hum Retrovir 2004; 20: 860-70.
37. Peters BS, Cheingsong-Popov R, Callow D, Foxall R, Patou G, Hodgkin K, et al. A pilot phase II study of the safety and immunogenicity of HIV p17/p24: VLP (p24-VLP) in symptomatic HIV seropositive subjects. J Infect 1997; 35: 231-5.
38. Smith D, Gow I, Colebunders R, Weller I, Tchamouroff S, Weber J, et al. Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline. HIV Med 2001; 2: 272-275.
39. Veenstra J, Williams IG, Colebunders R, Dorrell L, Tchamouroff SE, Patou G, et al. Immunization with recombinant p17/p24: Ty virus-like particles in human immunodeficiency virus-infected persons. J Infect Dis 1996; 174: 862-866.
40. Lindenburg CE, Stolte I, Langendam MW, Miedema F, Williams IG, Colebunders R, et al. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24: Ty virus-like particles on HIV-1 disease progression. Vaccine 2002; 20: 2343-7.
41. Ziegner UH, Peters G, Jolly DJ, Mento SJ, Galpin J, Prussak CE, et al. Cytotoxic T-lymphocyte induction in asymptomatic HIV-1-infected patients immunized with Retrovector-transduced autologous fibroblasts expressing HIV-1IIIB Env/Rev proteins. AIDS 1995; 9: 43-50.
42. Zagury D, Bernard J, Halbreich A, Bizzini B, Carelli C, Achour A, et al. One-year follow-up of vaccine therapy in HIV-infected immune-deficient individuals: a new strategy. J Acquir Immune Defic Syndr 1992; 5: 676-81.
43. Tubiana R, Gomard E, Fleury H, Gougeon ML, Mouthon B, Picolet H, et al. Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity. AIDS 1997; 11: 819-820.
44. Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002; 186: 634-643.
45. Ratto-Kim S, Loomis-Price LD, Aronson N, Grimes J, Hill C, Williams C, et al. Comparison between env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults. J Acquir Immune Defic Syndr 2003; 32: 9-17.
46. Perrin L. Therapeutic vaccination in primary HIV infection, Quest trial. Vaccine 2002; 20: 2004-6.
47. Cosma A, Nagaraj R, Buhler S, Hinkula J, Busch DH, Sutter G, et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 2003; 22: 21-9.
48. Schedel I, Sutor GC, Hunsmann G, Jurkiewicz E. Phase II study of anti-CD4 idiotype vaccination in HIV positive volunteers. Vaccine 1999; 17: 1837-1845.
49. Wolfe EJ, Cavacini LA, Samore MH, Posner MR, Kozial C, Spino C, et al. Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1. Clin Pharm Ther 1996; 59: 662-7.
50. Cavacini LA, Samore MH, Gambertoglio J, Jackson B, Duval M, Wisnewski A, et al. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses 1998; 14: 545-50.
51. Armbruster C, Stiegler GM, Vcelar BA, Jager W, Michael NL, Vetter N, et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 2002; 16: 227-33.
52. Dezube BJ, Proper J, Zhang J, Choy VJ, Weeden W, Morrissey J, et al. A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a phase I study. J Infect Dis 2003; 187: 500-3.
53. Pett SL, Williams LA, Day RO, Lloyd AR, Carr AD, Clezy KR, et al. A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals. HIV Clin Trials 2004; 5: 91-8.
54. Gunthard HF, Gowland PL, Schupbach J, Fung MS, Boni J, Liou RS, et al. A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120. J Infect Dis 1994; 170: 1384-93.
55. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004; 189: 286-91.
56. Dezube BJ, Doweiko JP, Proper JA, Conway B, Hwang L, Terada M, et al. Monoclonal antibody hNM01 in HIV-Infected patients: a phase I study. J Clin Virol 2004; 31: S45-S47.
57. Castelli G, Famularo A, Semino C, Machi AM, Ceci A, Cannella G, et al. Detection of anti-erythropoietin antibodies in haemodialysis patients treated with recombinant human-erythropoietin. Pharmacol Res 2000; 41: 313-8.
58. Hasatomi K, Yasunaga H, Isomura T, Fukunaga S, Hirano A, Kosuga K, et al. The changes of the cell-mediated immunity in patients with administration of recombinant erythropoietin. Nippon Geka Gakkai Zassh 1992; 93: 518-22.
59. Gringeri A, Santagostino E, Mannucci PM, Tradati F, Cultraro D, Buzzi A, et al. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization. J Acquir Immune Defic Syndr 1994; 7: 978-88.
60. Cummins MJ, Philip C, Fox PC, Cummins JM. The clinical use of low dose orally administered interferon alpha, with emphasis on treatment of patients positive for human immunodeficiency virus. In: Bourinbaiar AS Ed. AIDS Vaccines and Related Topics. Research Signpost, Kerala, India, 2004; pp. 11-30.
61. Bourinbaiar AS, Nagorny R. Inhibitory effect of natural interferon alpha on HIV transmission from epithelial cells to lymphocytes in vitro. Eur J Pharmacol 1993; 230: 15-22.
62. Takebe N, Paredes J, Pino MC, Lownsbury WH, Agosti J, Krown SE. Phase I/ II trial of the type I soluble recombinant human interleukin-1 receptor in HIV-1-infected patients. J Interferon Cytokine Res 1998; 18: 321-6.
63. Losso MH, Belloso WH, Emery S, Benetucci JA, Cahn PE, Lasala MC, et al. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts ≥350/mm3. J Infect Dis 2000; 181: 1614-21.
64. Knysz B, Gasiorowski J, Inglot M, Rymer W, Szymczak A, Gladysz A. The role of therapeutic use of interleukin-2 in HIV infection. Przegl Epidemiol 2002; 56: 587-93.
65. Angel JB, Jacobson MA, Skolnik PR, Giordano M, Shapiro L, LeBeaut A, et al. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects. AIDS 2000; 14: 2503-8.
66. Kohl S, Sigaroudinia M, Charlebois ED, Jacobson MA. Interleukin-12 administered in vivo decreases human NK cell cytotoxicity and antibody-dependent cellular cytotoxicity to human immunodeficiency virus-infected cells. J Infect Dis 1996; 174: 1105-8.
67. Jacobson MA, Hardy D, Connick E, Watson J, DeBruin M. Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL. J Infect Dis 2000; 182: 1070-6.
68. Jacobson JM, Lederman MM, Spritzler J, Valdez H, Tebas P, Skowron G, et al. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection. J Infect Dis 2003; 188: 1804-14.
69. Ngu VA, Ambe F. Effective vaccines against and immunotherapy of the HIV: a preliminary report (1). J Cameroon Acad Sci 2001; 1: 2-8.
70. Abalaka JOA. Attempts to cure and prevent HIV/AlDS in central Nigeria between 1997 and 2002: Opening a way to a vaccine-based solution to the problem. Vaccine 2004; 22: 3819-3828.
71. Spier RE. Jerimiah Abalaka and HIV in Nigeria. Vaccine 2004; 22: 3817-8.
72. Abulafia-Lapid R, Bentwich Z, Keren-Zur Y, Cohen IR, Atlan H. T-cell vaccination against anti-CD4 autoimmunity in HIV-1 infected patients. J Clin Virol 2004; 31: S48-S54.
73. Abulafia-Lapid R, Mayan S, Bentwich Z, Keren-Zur Y, Avbramovitz Y, Cohen IR, et al. T-cell vaccination against anti-CD4 autoimmunity in HIV-1 subtypes B and C-infected patients - an extended open trial. Vaccine 2005; 23: 2149-53.
74. Atlan H, Cohen IR. T-cell vaccination for HIV-seropositive patients. In: Gupta S, Ed. Immunology of HIV Infection: Plenum Press, New York, 1996; pp. 535-559.
75. Jirathitikal V, Metadilogkul O, Bourinbaiar AS. Increased body weight and improved quality of life in AIDS patients following V-1 Immunitor administration. Eur J Clin Nutr 2004; 58: 110-115.
76. Jirathitikal V, Metadilogkul O, Bourinbaiar AS. Normalization of elevated liver enzymes due to V-1 Immunitor therapy. Electr J Biotechnol 2003; 6: 76-79.
77. Jirathitikal V, Sooksathan P, Metadilogkul O, Bourinbaiar AS. V-1 Immunitor: Oral AIDS vaccine with therapeutic and prophylactic potential. Vaccine 2003; 21-324-328.
78. Bourinbaiar AS, Jirathitikal V, Metadilogkul O, Sooksathan P, Aemsri S, Promdevich P, et al. Phase II placebo-controlled study of V-1 Immunitor as a therapeutic modality for treatment of HIV. J Clin Virol 2004; 31: S55-S62.
79. Metadilogkul O, Jirathitikal V, Bourinbaiar AS. Serodeconversion of HIV antibody-positive AIDS patients after treatment with V-1 Immunitor. In: Bourinbaiar AS, Ed. AIDS Vaccines and Related Topics. Research Signpost, Kerala, India, 2004; pp. 77-87.
80. Metadilogkul O, Jirathitikal V, Bourinbaiar AS. Survival of endstage patients receiving V-1 Immunitor. HIV Clin Trials 2002; 3: 258-259.
81. Lambert JS, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, Weinhold K, et al. A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine 2001; 19: 3033-42.
82. Davis KC, Hayward A, Ozturk G, Kohler PF. Lymphocyte transfusion in case of acquired immunodeficiency syndrome. Lancet 1983; 1: 599-600.
83. Lane HC, Masur H, Longo DL, Klein HG, Rook AH, Quinnan GV Jr, et al. Partial immune reconstitution in a patient with the acquired immunodeficiency syndrome. N Engl J Med 1984; 311: 1099-103.
84. Bruster HT, Kuntz BM, Scheja JW. Autovaccination plus heat-inactivated autologous plasma in AIDS patients. Lancet 1988; 1: 1284-5.
85. Vilmer E, Rhodes-Feuillette A, Rabian C, Benbunan M, Meletis J, Devergie A, et al. Clinical and immunological restoration in patients with AIDS after marrow transplantation, using lymphocyte transfusions from the marrow donor. Transplantation 1987; 44: 25-9.
86. Verdonck LF, de Gast GC, Lange JM, Schuurman HJ, Dekker AW, Bast BJ. Syngeneic leukocytes together with suramin failed to improve immunodeficiency in a case of transfusion-associated AIDS after syngeneic bone marrow transplantation. Blood 1988; 71: 666-71.
87. Lane HC, Zunich KM, Wilson W, Cefali F, Easter M, Kovacs JA, et al. Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection. Ann Intern Med 1990; 113: 512-9.
88. Bex F, Hermans P, Sprecher S, Achour A, Badjou R, Desgranges C, et al. Syngeneic adoptive transfer of anti-human immunodeficiency virus (HIV-1)-primed lymphocytes from a vaccinated HIV-seronegative individual to his HIV-1-infected identical twin. Blood 1994; 84: 3317-26.
89. Tsoukas CM, Turner HM, Hatzakis GE, Blake GP, Goodhew JE, Kilby DL, et al. Improvement of HIV-specific immunity in HIV-infected twins treated with highly active antiretroviral therapy, interleukin 2, and syngeneic adoptively transferred cells. AIDS Res Hum Retroviruses 2001; 17: 887-900.
90. Ho M, Armstrong J, McMahon D, Pazin G, Huang XL, Rinaldo C, et al. A phase 1 study of adoptive transfer of autologous CD8+ T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS. Blood 1993; 81: 2093-101.
91. Klimas N, Patarca R, Walling J, Garcia R, Mayer V, Moody D, et al. Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion. AIDS 1994; 8: 1073-81.
92. Koenig S, Conley AJ, Brewah YA, Jones GM, Leath S, Boots LJ, et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1995, 1: 330-6.
93. Lieberman J, Skolnik PR, Parkerson GR 3rd, Fabry JA, Landry B, Bethel J, et al. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood 1997; 90: 2196-206.
94. Trickett AE, Kelly M, Cameron BA, Lloyd A, Ffrench RA, Dwyer JM. A preliminary study to determine the effect of an infusion of cryopreserved autologous lymphocytes on immunocompetence and viral load in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 129-36.
95. Triozzi PL, Aldrich W, Bresler HS, Para MF, Flancbaum LJ. Cellular immunotherapy of advanced human immunodeficiency virus type 1 infection using autologous lymph node lymphocytes: effects on chemokine production. J Infect Dis 1999; 179: 245-8.
96. Levine BL, Bernstein WB, Aronson NE, Schlienger K, Cotte J, Perfetto S, et al. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 2002; 8: 47-53.
97. www.biodeliverysciences.com/applications
98. Collier AC, Kalish LA, Busch MP, Gernsheimer T, Assmann SF, Lane TA, et al. Viral Activation Transfusion Study Group. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial. JAMA 2001; 285: 1592-601.
99. Krishnan A, Molina A, Zaia J, Smith D, Vasquez D, Kogut N, et al. Durable remissions with autologous stem cell transplantation for high risk HIV-associated lymphomas. Blood 2005; 105: 874-8.
100. Gabarre J, Marcelin AG, Azar N, Choquet S, Levy V, Levy Y, et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica 2004, 89: 1100-8.
101. Wang Y, Tao L, Mitchell E, Bravery C, Berlingieri P, Armstrong P, et al. Allo-immunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women. Nat Med 1999; 5: 1004-9.
102. Michaels MG, Kaufman C, Volberding PA, Gupta P, Switzer WM, Heneine W, et al. Baboon bone-marrow xenotransplant in a patient with advanced HIV disease: case report and 8-year follow-up. Transplantation 2004; 78: 1582-9.
103. Sapp M, Engelmayer J, Larsson M, Granelli-Piperno A, Steinman R, Bhardwaj N. Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. Immunol Lett 1999; 66: 121-8.
104. Grene E, Newton DA, Brown EA, Berzofsky JA, Gattoni-Celli S, Shearer GM. Semi-allogeneic cell hybrids stimulate HIV-1 envelope-specific cytotoxic T lymphocytes. AIDS 2000; 14: 1497-506.
105. Nehete PN, Chitta S, Hossain MM, Hill L, Bernacky BJ, Baze W, et al. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model. Vaccine 2001; 20: 813-25.
106. Lu W, Wu X, Lu Y, Guo W, Andrieu JM. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 2003; 9: 27-32.
107. Lisziewicz J, Bakare N, Lori F. Therapeutic vaccination for future management of HIV/AIDS. Vaccine 2003; 21: 620-3.
108. Shapero MH, Kundu SK, Engleman E, Laus R, van Schooten WC, Merigan TC. In vivo persistence of donor cells following adoptive transfer of allogeneic dendritic cells in HIV-infected patients. Cell Transplant 2000; 9: 307-17.
109. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nature Med 2004; 10: 1359-1365.
110. Garcia F, Lejeune M, Climent N, Gil C, Alcami J, Morente V, et al. Therapeutic Immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 Infection. J Infect Dis 2005, 191: 1680-5.
111. Chantratita W, Sukeepaisarncharoen W, Chandeying V, Kulpradist S, Israngkura Na Ayudhtaya B, Rugpao S, et al. Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (REMUNE) therapy in Thailand. HIV Med 2004; 5: 317-25.
112. Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 × 106/L CD4 cell counts: A randomized controlled trial. JAMA 2000; 284: 2193-2202.
113. Turner JL, Kostman JR, Aquino A, Wright D, Szabo S, Bidwell R, et al. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs. HIV Med 2001; 2: 68-77.
114. Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, Phillips AN, et al. QUEST Study Group. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005; 192: 607-17.
115. Fernandez-Cruz E, Navarro J, Rodriguez-Sainz C, Gil J, Moreno S, Gonzalez-Lahoz J, et al. The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection. Expert Rev Vaccines 2003; 2: 739-52.
116. Silvera P, Savary JR, Livingston V, White J, Manson KH, Wyand MH, et al. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques. Vaccine 2004; 23: 827-39.
117. Cohen J. Shots in the dark: The wayward search for an AIDS vaccine. W.W. Norton & Company Inc., 2001.
118. Niedrig M, Gregersen JP, Fultz PN, Broker M, Mehdi S, Hilfenhaus, J. Immune response of chimpanzees after immunization with the inactivated whole immunodeficiency virus (HIV-1), three different adjuvants and challenge. Vaccine 1993; 11: 67-74.
119. Ilyinskii PO, Lallos L, Castor T. Development of an Inactivated HIV Vaccine. Abstr #192. AIDS Vaccine 2001. September 5-8, 2001, Philadelphia, PA.
120. Race E, Frezza P, Stephens DM, Davis D, Polyanskaya N, Cranage M, et al. An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses. Vaccine 1995; 13: 54-60.
121. Grovit-Ferbas K, Hsu JF, Ferbas J, Gudeman V, Chen IS. Enhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1. J Virol 2000; 74: 5802-9
122. Lifson JD, Rossio JL, Piatak M Jr, Bess J Jr, Chertova E, Schneider DK, et al. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res Hum Retrovir 2004; 20: 772-87.
123. Karpas A, Hewlett IK, Hill F, Gray J, Byron N, Gilgen D, Bally V, et al. Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex. Proc Natl Acad Sci USA 1990; 87: 7613-7.
124. Jackson GG, Perkins JT, Rubenis M, Paul DA, Knigge M, Despotes JC, et al. Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet 1988; 2: 647-52.
125. Karpas A, Hill F, Youle M, Cullen V, Gray J, Byron N, et al. Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. Proc Natl Acad Sci USA 1988; 85: 9234-7.
126. Blick G, Scott WF, Crook SW, Buchanan S, Garton T, Hopkins U, et al. Passive immunotherapy in advanced HIV infection and therapeutic plasmapheresis in asymptomatic HIV-positive individuals: a four-year clinical experience. Biotherapy 1998, 11: 7-14.
127. Jacobson JM, Colman N, Ostrow NA, Simson RW, Tomesch D, Marlin L, et al. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis 1993; 168: 298-305.
128. Vittecoq D, Chevret S, Morand-Joubert L, Heshmati F, Audat F, Bary M, et al. Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci USA 1995; 92: 1195-9.
129. Fletcher CV, Goodroad BK, Cummins LM, Henry K, Balfour HH Jr, Rhame FS. Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS. Antimicrob Agents Chemother 1997; 41: 1571-4.
130. Lambert JS, Mofenson LM, Fletcher CV, Moye J Jr, Stiehm ER, Meyer WA 3rd, et al. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. J Infect Dis 1997; 175: 283-91.
131. Stiehm ER, Fletcher CV, Mofenson LM, Palumbo PE, Kang M, Fenton T, et al. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). J Infect Dis 2000; 181: 548-54.
132. Guay LA, Musoke P, Hom DL, Nakabiito C, Bagenda D, Fletcher CV, et al. Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. AIDS 2002; 16: 1391-400.
133. Pardridge WM, Buciak J, Yang J, Diagne A. Treatment of human immunodeficiency virus-infected lymphocytes with cationized human immunoglobulins. J Infect Dis 1994; 170: 563-9.
134. Cummins LM, Weinhold KJ, Matthews TJ, Langlois AJ, Perno CF, Condie RM, et al. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors. Blood 1991; 77: 1111-7.
135. Morand-Joubert L, Vittecoq D, Roudot-Thoraval F, Mariotti M, Lefrere F, Heshmati F, et al. Virological and immunological data of AIDS patients treated by passive immunotherapy (transfusions of plasma rich in HIV-1 antibodies). Vox Sang 1997; 73: 149-54.
136. Preble OT, Sonnabend JA. AIDS from the perspective of experimental pathology. J Exp Pathol 1983; 1: 3-6.
137. Stott EJ. Anti-cell antibody in macaques. Nature 1991; 353: 393.
138. Langlois AJ, Weinhold KJ, Matthews TJ, Greenberg ML, Bolognesi DP. The ability of certain SIV vaccines to provoke reactions against normal cells. Science 1992; 255: 292-293.
139. Maksyutov AZ, Bachinskii AG, Bazhan SI, Ryzhikov EA, Maksyutov ZA. Exclusion of HIV epitopes shared with human proteins is prerequisite for designing safer AIDS vaccines. J Clin Virol 2004; 31: S26-S38.
140. Root-Bernstein RS. Antigenic complementarity among AIDS-associated infectious agents and molecular mimicry of lymphocyte proteins as inducers of lymphocytotoxic antibodies and circulating immune complexes. J Clin Virol 2004;31: S16-S25.
141. Hofmann B, Langhoff E, Lindhardt BO, Odum N, Hyldig-Nielsen JJ, Ryder LP, et al. Investigation of immunosuppressive properties of inactivated human immunodeficiency virus and possible neutralization of this effect by some patient sera. Cell Immununol 1989; 121: 336-48.
142. Kang Y, Melo EF, Scott DW. An ongoing immune response to HIV envelope gp120 in human CD4-transgenic mice contributes to T cell decline upon intravenous administration of gp120. Eur J Immunol 1998; 28: 2253-64.
143. Lopalco L, Pastori C, Cosma A, Burastero SE, Capiluppi B, Boeri E, et al. Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity. AIDS Res Hum Retrovir 2000; 16: 109-115.
144. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev 2002; 1: 329-37.
145. Spear GT, Olinger GG, Saifuddin M, Gebel HM. Human antibodies to major histocompatibility complex alloantigens mediate lysis and neutralization of HIV- 1 primary isolate virions in the presence of complement. J Acquir Immune Defic Syndr 2001; 26: 103-110.
146. Salkowitz JR, Purvis SF, Meyerson H, Zimmerman P, O'Brien TR, Aledort L, et al. Characterization of high-risk HIV-1 seronegative hemophiliacs. Clin Immunol 2001; 98: 200-11.
147. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino, RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002; 169: 3400-3406.
148. Deeks SG, Walker BD. The immune response to AIDS virus infection: good, bad, or both? J Clin Invest 2004; 113: 808-10.
149. Andrieu JM, Even P, Venet A, Tourani JM, Stern M, Lowenstein W, et al. Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease. Clin Immunol Immunopathol 1988; 47: 181-98.
150. Bourinbaiar AS, Lopes R, Fruhstorfer EC. Comparative study of cyclosporine A and azidothymidine (AZT) for their effects on HIV replication and immune function of T lymphocytes. Cell Pharmacol AIDS Sci 1996; 3: 163-169.
151. Ziegler JL, Stites DP. Hypothesis: AIDS is an autoimmume disease directed at the immune system and triggered by a lymphotropic retrovirus. Clin Immunol Immunopathol 1986; 41: 305-13.
152. Hoffmann GW, Kion TA, Grant MD. An idiotypic network model of AIDS immunopathogenesis. Proc Natl Acad Sci USA 1991; 88: 3060-4.
153. Shearer GM, Clerici M, Dalgleish A. Alloimmunization as an AIDS vaccine? Science 1993; 262: 161-2.
154. Oxford JS, Frezza P, Race E. Challenges and strategies for AIDS vaccine development. Vaccine 1991,11: 612-4.
155. Atlan H, Gersten MJ, Salk PL, Salk J. Mechanisms of autoimmunity and AIDS: prospects for therapeutic intervention. Res Immunol 1994; 145: 165-83.
156. Kiprov DD, Sheppard HW, Hanson CV. Alloimmunization to prevent AIDS? Science 1994; 263: 737-8.
157. Bourinbaiar AS, Lee-Huang S. Rational problems associated with the development of cellular approaches in controlling HIV spread. Adv Exp Med Biol 1995; 374: 71-89.
158. Lehner T, Shearer GM, Hackett CJ, Schultz A, Sharma OK. Alloimmunization as a strategy for vaccine design against HIV/AIDS. AIDS Res Hum Retrovir 2000; 16: 309-13.
159. Gould SJ, Booth AM, Hildreth JE. The Trojan exosome hypothesis. Proc Natl Acad Sci USA 2003; 100: 10592-7.
160. Chase MW. Inhibition of experimental drug allergy by prior feeding of the sensitivity agent. Proc Soc Exp Biol Med 1946; 61: 257-259.
161. Hafler DA, Weiner HL. Immunologic mechanisms and therapy in multiple sclerosis. Immunol Rev 1995; 144: 75-107.
162. Sela M, Mozes E. Therapeutic vaccines in autoimmunity. Proc Natl Acad Sci USA 2004; 101(Suppl 2): 14586-92.
163. Cohen IR. T-cell vaccination for autoimmune disease: a panorama. Vaccine 2001; 20: 706-10.
164. Zhang J. T-cell vaccination for autoimmune diseases: immunologic lessons and clinical experience in multiple sclerosis. Expert Rev Vaccines 2002; 1: 285-92.
165. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, doubleblind, phase II trial. Lancet 2001; 358: 1749-53.
166. Chaillous L, Lefevre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orate group. Lancet 2000; 356: 545-9.
167. Margalit M, Ilan Y. Oral immune regulation: a novel method for modulation of anti-viral immunity. J Clin Virol 2004; 31: S63-8.
168. Bourinbaiar AS, Jirathitikal J, Hoffmann GW, Lu N-Q. AIDS vaccines and immunotherapy of infertility. Zhonghua Nan Ke Xue 2005; 11: 163-9.
169. Leith JG, Clark DA, Matthews TJ, Rosenthal KL, Luscher MA, Barber BH, et al.Assessing human alloimmunization as a strategy for inducing HIV type 1 neutralizing anti-HLA responses. AIDS Res Hum Retrovir 2003; 19: 957-65.
170. Peters B, Whittall T, Babaahmady K, Gray K, Vaughan R, Lehner T. Effect of heterosexual intercourse on mucosal alloinmumisation and resistance to HIV-1 infection. Lancet 2004; 363: 518-24.
171. Medzhitov R, Janeway CA Jr. Innate immune recognition and control of adaptive immune responses. Semin Immunol 1998; 10: 351-3.
172. Bourinbaiar AS, Metadilogkul O, Jirathitikal V. Mucosal AIDS vaccines. Viral Immunol 2003; 16: 427-445
173. Bourinbaiar AS, Abulafia-Lapid R. Autoimmunity, alloimmunization, and immunotherapy of AIDS. Autoimmun Rev 2005; 4: 403-36.
174. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 2004; 10(3):315-36
175. Pereira CF, Paridaen JT. Anti-HIV drug development--an overview. Curr Pharm Des 2004; 10(32): 4005-37.
176. Thomas SA. Anti-HIV drug distribution to the central nervous system. Curr Pharm Des 2004; 10(l2): 1313-24.